78 related articles for article (PubMed ID: 36690799)
1. Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Pons-Tostivint E; Hulo P; Guardiolle V; Bodot L; Rabeau A; Porte M; Hiret S; Demontrond P; Curcio H; Boudoussier A; Veillon R; Mayenga M; Dumenil C; Chatellier T; Gourraud PA; Mazieres J; Bennouna J
Cancer Immunol Immunother; 2023 Jun; 72(6):1881-1890. PubMed ID: 36690799
[TBL] [Abstract][Full Text] [Related]
2. A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients.
Porte M; Vaudron A; Crequit P; Vaugier L; Chatellier T; Fronteau C; Raimbourg J; Goronflot T; Bennouna J; Pons-Tostivint E
Clin Lung Cancer; 2024 Mar; 25(2):e101-e111.e2. PubMed ID: 38072729
[TBL] [Abstract][Full Text] [Related]
3. Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab.
Bureau M; Chatellier T; Perennec T; Goronflot T; Greilsamer C; Chene AL; Affi R; Frampas E; Bennouna J; Pons-Tostivint E
Cancer Immunol Immunother; 2022 Jul; 71(7):1747-1756. PubMed ID: 34839373
[TBL] [Abstract][Full Text] [Related]
4. First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).
Descourt R; Greillier L; Perol M; Ricordel C; Auliac JB; Falchero L; Gervais R; Veillon R; Vieillot S; Guisier F; Marcq M; Justeau G; Bigay-Game L; Bernardi M; Fournel P; Doubre H; Pinsolle J; Amrane K; Chouaïd C; Decroisette C
Cancer Immunol Immunother; 2023 Jan; 72(1):91-99. PubMed ID: 35729418
[TBL] [Abstract][Full Text] [Related]
5. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Leonetti A; Perrone F; Puntoni M; Maglietta G; Bordi P; Bria E; Vita E; Gelsomino F; De Giglio A; Gelibter A; Siringo M; Mazzoni F; Caliman E; Genova C; Bertolini F; Guaitoli G; Passiglia F; Delcuratolo MD; Montrone M; Cerea G; Pasello G; Roca E; Belluomini L; Cecere FL; Guida A; Manzo A; Adamo V; Rastelli F; Bulotta A; Citarella F; Toschi L; Zoratto F; Cortinovis DL; Berardi R; Follador A; Carta A; Camerini A; Salerno F; Silva RR; Baldini E; Cortellini A; Brighenti M; Santoni M; Malorgio F; Caminiti C; Tiseo M
Eur J Cancer; 2024 May; 202():114006. PubMed ID: 38489861
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90.
Shah M; Mamtani R; Marmarelis ME; Hennessy S
Clin Lung Cancer; 2023 May; 24(3):235-243. PubMed ID: 36935244
[TBL] [Abstract][Full Text] [Related]
7. Real world prognostic utility of platelet lymphocyte ratio and nutritional status in first-line immunotherapy response in stage IV non-small cell lung cancer.
MacDonald M; Poei D; Leyba A; Diep R; Chennapan K; Leon C; Xia B; Nieva JJ; Hsu R
Cancer Treat Res Commun; 2023; 36():100752. PubMed ID: 37611343
[TBL] [Abstract][Full Text] [Related]
8. Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy.
Li M; Zhao S; Lopez G; Secor A; Das P; Surya N; Grogan M; Patel S; Chakravarthy K; Miah A; Spakowicz D; Tinoco G; Li Z; Wei L; He K; Bertino E; Alahmadi A; Memmott R; Kaufman J; Shields PG; Carbone DP; Presley CJ; Otterson GA; Owen DH
Cancer Immunol Immunother; 2023 Jul; 72(7):2067-2074. PubMed ID: 36795122
[TBL] [Abstract][Full Text] [Related]
9. Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy.
Chaunzwa TL; Qian JM; Li Q; Ricciuti B; Nuernberg L; Johnson JW; Weiss J; Zhang Z; MacKay J; Kagiampakis I; Bikiel D; Di Federico A; Alessi JV; Mak RH; Jacob E; Awad MM; Aerts HJWL
JAMA Oncol; 2024 May; ():. PubMed ID: 38780929
[TBL] [Abstract][Full Text] [Related]
10. Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan.
Abu Hejleh T; AlSawalha K; Abdel Hafiz S; Al-Batsh T; Abu Hejleh R; Yaser S; Abu Jazar H; Khader J; Alnsour A; Mohamad I; Abdel Jalil R; Abu-Shanab A; Gharaibeh A; Abu Shattal M; Alibraheem A; Haddad H; Mahmoud N; Obeidat S; Al-Jaghbeer MJ; Furqan M; Cortellini A; Velcheti V; Al-Rabi K
Front Oncol; 2024; 14():1369126. PubMed ID: 38746680
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.
Furqan M; Karanth S; Goyal RK; Cai B; Rombi J; Davis KL; Caro N; Saliba T
Future Oncol; 2024 Apr; ():1-11. PubMed ID: 38629593
[No Abstract] [Full Text] [Related]
12. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook.
Horvath L; Thienpont B; Zhao L; Wolf D; Pircher A
Mol Cancer; 2020 Sep; 19(1):141. PubMed ID: 32917214
[TBL] [Abstract][Full Text] [Related]
13. Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer.
Onn A; Gottfried T; Stemmer A; Appel S; Lawrence YR; Urban D; Beller T; Daher S; Bar J
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199805
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060.
Tozuka T; Minegishi Y; Yamaguchi O; Watanabe K; Toi Y; Saito R; Nagai Y; Tamura Y; Shoji T; Odagiri H; Ebi N; Sakai K; Kanaji N; Izumi M; Soda S; Watanabe S; Morita S; Kobayashi K; Seike M
JTO Clin Res Rep; 2024 Apr; 5(4):100655. PubMed ID: 38706978
[TBL] [Abstract][Full Text] [Related]
15. Too Much of a Good Thing: The Association of Elevated Vitamin B12 Levels and Outcomes in Patients With Cancer Treated With Immunotherapy.
Turgeman I; Benaim AR; Regev-Tsur S; Turgeman S; Abu Amna M; Badran O; Bar-Sela G
J Immunother; 2024 May; 47(4):117-122. PubMed ID: 37909180
[TBL] [Abstract][Full Text] [Related]
16. Real-world impact of patient-reported outcome measurement on overall survival, healthcare use and treatment discontinuation in cancer patients.
Yan JT; Boyne DJ; Lo E; Farah E; O'Sullivan DE; Cheung WY
J Comp Eff Res; 2023 Oct; 12(10):e230061. PubMed ID: 37555588
[No Abstract] [Full Text] [Related]
17. Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study.
Saeed A; Hildebrand H; Park R; Al-Jumayli M; Abbasi S; Melancon T; Saeed A; Al-Rajabi R; Kasi A; Baranda J; Williamson S; Sun W
J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32824968
[TBL] [Abstract][Full Text] [Related]
18. Comparing prospectively assigned trial and real-world lung cancer patients.
Walker B; Ray HE; Shao P; D'Ambrosio C; White C; Walker MS
J Comp Eff Res; 2024 May; ():e230176. PubMed ID: 38785683
[No Abstract] [Full Text] [Related]
19. DeePaN: deep patient graph convolutional network integrating clinico-genomic evidence to stratify lung cancers for immunotherapy.
Fang C; Xu D; Su J; Dry JR; Linghu B
NPJ Digit Med; 2021 Feb; 4(1):14. PubMed ID: 33531613
[TBL] [Abstract][Full Text] [Related]
20. Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.
Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
Curr Oncol; 2023 May; 30(6):5299-5308. PubMed ID: 37366885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
